Cargando…
Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro
This report describes the application of real-time PCR for testing antivirals against highly pathogenic viruses such as Lassa virus, SARS coronavirus and Ebola virus. The test combines classical cell culture with a quantitative real-time PCR read-out. The assay for Lassa virus was validated with rib...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126008/ https://www.ncbi.nlm.nih.gov/pubmed/15451189 http://dx.doi.org/10.1016/j.antiviral.2004.05.001 |
_version_ | 1783516064362004480 |
---|---|
author | Günther, Stephan Asper, Marcel Röser, Christina Luna, Luciano K.S. Drosten, Christian Becker-Ziaja, Beate Borowski, Peter Chen, Huan-Ming Hosmane, Ramachandra S. |
author_facet | Günther, Stephan Asper, Marcel Röser, Christina Luna, Luciano K.S. Drosten, Christian Becker-Ziaja, Beate Borowski, Peter Chen, Huan-Ming Hosmane, Ramachandra S. |
author_sort | Günther, Stephan |
collection | PubMed |
description | This report describes the application of real-time PCR for testing antivirals against highly pathogenic viruses such as Lassa virus, SARS coronavirus and Ebola virus. The test combines classical cell culture with a quantitative real-time PCR read-out. The assay for Lassa virus was validated with ribavirin, which showed an IC(50) of 9 μg/ml. Small-scale screening identified a class of imidazole nucleoside/nucleotide analogues with antiviral activity against Lassa virus. The analogues contained either dinitrile or diester groups at the imidazole 4,5-positions, and many of which possessed an acyclic sugar or sugar phosphonate moiety at the imidazole 1-position. The IC(50) values of the most active compounds ranged from 5 to 21 μg/ml. The compounds also inhibited replication of SARS coronavirus and Ebola virus in analogous assays, although to a lesser extent than Lassa virus. |
format | Online Article Text |
id | pubmed-7126008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71260082020-04-08 Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro Günther, Stephan Asper, Marcel Röser, Christina Luna, Luciano K.S. Drosten, Christian Becker-Ziaja, Beate Borowski, Peter Chen, Huan-Ming Hosmane, Ramachandra S. Antiviral Res Short Communication This report describes the application of real-time PCR for testing antivirals against highly pathogenic viruses such as Lassa virus, SARS coronavirus and Ebola virus. The test combines classical cell culture with a quantitative real-time PCR read-out. The assay for Lassa virus was validated with ribavirin, which showed an IC(50) of 9 μg/ml. Small-scale screening identified a class of imidazole nucleoside/nucleotide analogues with antiviral activity against Lassa virus. The analogues contained either dinitrile or diester groups at the imidazole 4,5-positions, and many of which possessed an acyclic sugar or sugar phosphonate moiety at the imidazole 1-position. The IC(50) values of the most active compounds ranged from 5 to 21 μg/ml. The compounds also inhibited replication of SARS coronavirus and Ebola virus in analogous assays, although to a lesser extent than Lassa virus. Elsevier B.V. 2004-09 2004-06-15 /pmc/articles/PMC7126008/ /pubmed/15451189 http://dx.doi.org/10.1016/j.antiviral.2004.05.001 Text en Copyright © 2004 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Günther, Stephan Asper, Marcel Röser, Christina Luna, Luciano K.S. Drosten, Christian Becker-Ziaja, Beate Borowski, Peter Chen, Huan-Ming Hosmane, Ramachandra S. Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro |
title | Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro |
title_full | Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro |
title_fullStr | Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro |
title_full_unstemmed | Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro |
title_short | Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro |
title_sort | application of real-time pcr for testing antiviral compounds against lassa virus, sars coronavirus and ebola virus in vitro |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126008/ https://www.ncbi.nlm.nih.gov/pubmed/15451189 http://dx.doi.org/10.1016/j.antiviral.2004.05.001 |
work_keys_str_mv | AT guntherstephan applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro AT aspermarcel applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro AT roserchristina applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro AT lunalucianoks applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro AT drostenchristian applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro AT beckerziajabeate applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro AT borowskipeter applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro AT chenhuanming applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro AT hosmaneramachandras applicationofrealtimepcrfortestingantiviralcompoundsagainstlassavirussarscoronavirusandebolavirusinvitro |